In q1 resultaten methanex: wat hoogtepunten wbt OCI gerelateerd
Methanex (NASDAQ:MEOH) Corporation reported robust financial results for Q4 2024, driven by strong production and strategic initiatives. The company highlighted its record safety performance and progress in integrating its upcoming OCI acquisition. However, the stock market response was muted, reflecting broader industry trends.
Key Takeaways
Methanex achieved a Q4 2024 adjusted EBITDA of 24 million dollars.
The company recorded its best safety performance on record.
Methanex is on track to complete its OCI acquisition in Q2 2025.
Global methanol demand is expected to grow by 3 million tonnes in 2025.
Methanex forecasts a Q1 2025 average realized price of 3.95 to 4.05 dollars per tonne, anticipating significantly higher adjusted EBITDA compared to Q4 2024. The company plans to complete its OCI acquisition in Q2 2025 and is prioritizing debt reduction and financial flexibility. Methanex expects global methanol demand to continue growing at a similar pace to 2024.
During the earnings call, analysts inquired about the OCI acquisition process, Iranian methanol supply constraints, and Methanex's inventory build strategy. The management confirmed that the regulatory approval process for the OCI acquisition is on track and discussed strategies to mitigate potential impacts from trade tariffs.
Hamir Patel, Analyst, CIBC Capital Markets: an update on how the regulatory approvals for the OCI deal are progressing? And should we still assume a close sometime in the first half?
Rich Sumner, President and CEO, Methanex Corporation: Yes. It's thanks, Hamre. We're progressing things well as planned, and we're going through the process in both Europe and the U. S. As we discussed previously.
And right now, the expectation is to close in the first half. It's looking like it's going to be looking like it's more Q2 close sometime in the first half of the year, but a Q2 close right now. So we're getting things all prepared for that and starting to plan integration as we get ready for regulatory approval.